LD-2 disclosure · Registration
AMGEN
Coverage · Registration filing — establishes the registrant/client relationship. No periodic income or expenses are reported at registration.
Client
- Name
- AMGEN
- Description
- Biopharmaceutical manufacturer
- Location
- California · United States of America
Registrant
- Location
- Arlington, Virginia, United States of America
Lobbying activities
3 issuesMedicare/Medicaid
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
LobbyistsJEANNE HAGGERTY
Budget/Appropriations
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
LobbyistsJEANNE HAGGERTY
Health Issues
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
LobbyistsJEANNE HAGGERTY